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Methods: Using data from 1322 patients enrolled in two phase-III studies (EXPEDITION 1
[NCT00905372] and 2 [NCT00904683]) of intravenous solanezumab in outpatients with mild AD
dementia, correlations between patient- and caregiver-assessed QOL and between QOL and clinical
outcome measures were examined. Longitudinal effects of solanezumab over 80 weeks were
explored, controlling for patient and caregiver baseline characteristics.
Results: Caregivers rated patients’ QOL worse than did patients themselves. Patients’ QOL was
correlated, albeit modestly, with clinical/health measures. Patients’ QOL changed minimally over
80 weeks, although a treatment effect of solanezumab on QOL was detected.
Discussion: Further investigations are needed to determine the optimal measures with which to
quantify and qualify QOL of patients with mild AD.
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Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disease that is usually characterized by an initial gradual
decline in the ability to remember new information, followed
bydeteriorationofadditional aspectsofmemoryandother areas
of cognition such as language, planning, and organization [1].
Given the wide range of cognitive and functional impair-
ment levels represented across the spectrum of this progressive
disease, one of the biggest challenges for clinical trial research
in AD is the selection of appropriate measurable outcomes for
determining treatment effects. This challenge is exacerbated by
the fact that, even early in the disease course, AD is sometimes
characterized by decreased insight that impairs the person’sthor. Tel.: 317-651-9881; Fax: 317-276-5791.
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//creativecommons.org/licenses/by-nc-nd/4.0/).ability to understand the impact of their disease on daily func-
tioning [2], a clinical phenomenon known as anosognosia.
Indeed, awareness of memory impairment begins to rapidly
decline 2–3 years before the onset of dementia [2], suggesting
that patient recall is of limited value in patients with AD.
Therefore, caregiver reports and performance-based measures
of cognition for patients are used for many clinical trials.
Clinical trials use outcomes designed to track progression
of the disease, such as the Mini–Mental State Examination
(MMSE) [3] and the Alzheimer’s Disease Assessment
Scale–Cognitive subscale (ADAS-Cog) [4], which measure
cognitive function; the Neuropsychiatric Inventory (NPI)
[5], which assesses psycho-behavioral symptomatology
(and its brief form, the NPI-Q [6]); andmeasures of activities
of daily living (ADL) such as the Alzheimer’s Disease Coop-
erative Study–ADL Inventory (ADCS-ADL) [7].
In addition to clinical measures of disease progression,
clinicians and others want to understand the clinicalthe Alzheimer’s Association. This is an open access article under the CCBY-
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(QOL) is proposed as one method of doing this. QOL is an
important consideration in AD because of the devastating
impact of this currently incurable disease on patients and
caregivers. From the patient’s perspective, QOL measures
may assist understanding of the magnitude of the impact
of treatment intervention, whereas, from a payer perspective,
QOL measures can provide a common metric of comparison
across disease states. Although the effects of AD on care-
giver QOL have been well documented [8–10], until
recently, few studies had evaluated the QOL of patients
with AD, and data are limited regarding the effects of
treatment on patients’ QOL [11]. Indeed, whether QOL pro-
vides an appropriate reflection of clinical meaningfulness in
patients with AD is unclear. In addition, discrepancies be-
tween patients’ and proxy/caregivers’ assessment of patient
QOL have been observed in AD [8,12,13].
Currently available treatments have focused on improving
symptoms of AD by targeting neurotransmitters; newer treat-
ments aim to slow disease progression by targeting the under-
lying pathophysiology of AD (e.g., amyloid-b or tau protein)
[14–16]. Solanezumab is a monoclonal antibody that binds to
the mid-domain of soluble amyloid-b monomers and has
been investigated in two completed phase-III clinical trials,
EXPEDITION and EXPEDITION 2 [17,18]. In each of
these studies, solanezumab and placebo did not differ
significantly with respect to their effects on the cognition,
functioning, or QOL of patients with mild-to-moderate AD
dementia. However, in a pooled secondary analysis of data
from both studies, a statistically significant treatment effect
of solanezumab was observed on cognitive and functional
end points (the 14-point ADAS-Cog [ADAS-Cog 14],
MMSE, and instrumental ADCS-ADL [ADCS-iADL]) for
patients in the mild dementia subgroup [18].
This study explores the characteristics of the QOL in AD
scale (QOL-AD) within the context of the EXPEDITION
and EXPEDITION 2 solanezumab trials to inform its applica-
bility in future clinical trials. In a secondary analysis of pooled
data from the subgroups of patients with mild AD dementia in
these two clinical trials, we examined correlations between
patient- and caregiver-assessed QOL and between QOL and
clinical outcomemeasures; we also explored any longitudinal
solanezumab treatment effect on QOL over 80 weeks.2. Methods
Data for these analyses were obtained from two
identically designed phase-III multinational, randomized,
double-blind, placebo-controlled studies of intravenous sol-
anezumab 400 mg every 4 weeks in outpatients with mild-
to-moderate AD dementia (EXPEDITION/EXPEDITION
2) [17,18].
Eligible patients were aged at least 55 years, had probable
AD based on National Institute of Neurological and Commu-
nicative Disorders and Stroke/Alzheimer’s Disease and
Related Disorders Association criteria [19], had no significantdepression on a screening questionnaire, and were otherwise
in good health. Patients were also required to have a consis-
tent caregiver (defined as an individual who knew them
well and had contact with them for at least 10 hours each
week) to accompany them to study visits and complete
caregiver-rated scales. Although patients with MMSE scores
of 16–26 were included in these studies, the current analysis
was limited to the subset of patients with mild AD dementia
(MMSE 20–26) receiving either solanezumab or placebo,
given the treatment effect noted in this prespecified subgroup
in the previous pooled analysis [18].
The protocols for these two studies were approved by the
institutional review board of each participating institution,
and all participants provided written informed consent.2.1. Outcome measure
QOL was measured using the 13-item QOL-AD scale (to-
tal score range 13–52; higher scores indicate better QOL)
[20–22]. The QOL-AD scale uses a scale of 1–4 (poor, fair,
good, or excellent) to rate a variety of life domains, including
the patient’s physical health, mood, relationships, activities,
and ability to complete tasks [21,22]. Both patients (self-
assessed) and caregivers (proxy-assessed) completed the
QOL-AD. To provide an assessment that may be more
balanced than either score alone, a weighted total score was
also adopted and calculated ([patient-assessed total
score! 21 caregiver-assessed total score]/3) [20]. Baseline,
end point, and change over time from baseline to 80weeks for
patient-assessed QOL, caregiver-assessed QOL, and
weighted QOL were calculated. Psychometric properties of
the scale have been described in previous work [20–22].
The QOL-AD has been shown to have excellent internal con-
sistency reliability for both patient and caregiver reports
(a 5 0.84 and 0.86, respectively) at all levels of cognitive
functioning and good validity as indicated by correlations
with measures of depression, day-to-day functioning, and
pleasant events frequency [20,21]. Thorgrimsen and
colleagues [22] reported the QOL-AD to have good content
validity, construct validity, interrater reliability (all Cohen’s
kappa values .0.70), test-retest reliability, and internal con-
sistency (Cronbach a coefficient of 0.82).2.2. Analyses
Baseline characteristics of patients with mild AD demen-
tia and their caregivers were summarized based on nonmiss-
ing data and presented as mean (standard deviation [SD]) or
as number and percentage of patients/caregivers by treat-
ment group and overall. Categorical variables were
compared between treatment groups using chi-squared or
Fisher’s exact test, and continuous variables were compared
using the two-sample t test.
The last observation carried forward (LOCF) data set,
with imputations for missing data, was used for analyses at
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correlation analyses and linear regression.
Unadjusted correlation analyses, using Spearman’s corre-
lation method, were performed at baseline and end point
(80 weeks) to determine correlations between patient- and
caregiver-assessed QOL-AD scores. Similar analyses were
also performed for the change in these scores from baseline
to end point. To estimate the strength of the association be-
tween change in QOL-AD from baseline to 80 weeks and
change over time in other outcome measures (MMSE,
ADAS-Cog 14, ADCS-ADL, ADCS-iADL, NPI total score,
NPI caregiver stress score, EuroQol 5-Dimensions [EQ-5D]
utility score, and EQ-5D visual analog scale [VAS] score),
partial correlation analyses were conducted using Spear-
man’s partial rank-order correlation while controlling for
baseline QOL-AD score, baseline of outcome variable exam-
ined, patient and caregiver baseline covariates and treatment
received at baseline (solanezumab vs. placebo). The baseline
covariates included the following patient and caregiver base-
line demographics and clinical characteristics: patient age,
sex, number of comorbidities, depression (yes/no), and
concomitant AD medications (yes/no); whether the patient
lived alone (yes/no); duration since AD diagnosis; duration
since AD onset; caregiver age, sex, and type; and region.
To assess how a change in one-unit score on other outcome
variables predicted change in unit score on the QOL-AD,
linear regression models, with change in QOL-AD as the
response variable and change in other outcomes as the explan-
atory variable, were fitted, after controlling for baseline QOL-
AD score, patient and caregiver core baseline covariates (see
previous paragraph) and treatment received at baseline (sola-
nezumab vs. placebo). The coefficient estimate and standard
error-associated P-value are reported.
To evaluate the treatment effects of solanezumab versus
placebo on QOL over 80 weeks, mixed model repeated mea-
sures (MMRM) analyses were conducted for QOL analysis
to test the treatment difference between least squares mean
at each post-baseline visit from baseline. The dependent var-
iable was the change from baseline in QOL scores. The
model included QOL scores at baseline, treatment (solane-
zumab/placebo), visit, treatment-by-visit interaction, and
core baseline covariates (see earlier paragraph), and visit
as a repeated measure. The model includes an unstructured
covariance matrix.
To further describe the treatment effects on QOL-AD
from baseline to 80 weeks, an effect size was calculated in
terms of the difference in QOL-AD between two means (sol-
anezumab treated vs. placebo) divided by a pooled baseline
SD. Required sample size was estimated using the derived
effect size and 80% power to demonstrate statistical differ-
ence with significance level set at a , .05.
Similar analyses using data from study completers were
conducted to verify the results from analyses of LOCF
data (data not shown).
All analyses were performed using SAS version 9.2 (SAS
Institute, Cary, NC, USA).3. Results
A total of 1322 patients with mild AD dementia were ran-
domized to receive solanezumab (n 5 659) or placebo
(n5 663) and are included in the analyses. Table 1 summa-
rizes the baseline characteristics for these patients and their
caregivers. Baseline patient and caregiver demographics and
characteristics did not differ significantly between treatment
groups except for NPI total score, which was lower in pa-
tients randomized to solanezumab than in those randomized
to placebo (P 5 .03), and EQ-5D VAS, which was higher in
patients randomized to solanezumab (P 5 .01).
QOL-AD scores at baseline were numerically higher
(better) when assessed by patients compared with caregivers
in both treatment groups (Table 2). In the solanezumab
group, mean (SD) patient-assessed scores were 37.7 (6.1),
and caregiver-assessed scores were 35.2 (6.2). Respective
mean (SD) scores in the placebo group were 37.9 (6.0) and
35.2 (6.1). As expected, weighted scores fell between the
respective patient- and caregiver-assessed scores.
3.1. Correlations between patient- and caregiver-assessed
QOL-AD
Although patient- and caregiver-assessed QOL-AD
scores were moderately correlated at baseline (r 5 0.48)
and week 80 (r 5 0.46), the change in patient-assessed
QOL-AD score was only weakly correlated with change in
caregiver-assessed QOL-AD score (r5 0.15), when consid-
ering the pooled patient population with mild AD dementia.
Similar findings were obtained when the solanezumab- and
placebo-treated populations were considered separately.
3.2. Relationships between QOL and clinical outcomes
Results of the partial correlation analyses indicated that
changes in patient-assessed QOL-AD scores had low corre-
lations with changes in other clinical/health end points,
whereas small-to-moderate correlations were observed be-
tween caregiver-assessed QOL-AD scores and other clin-
ical/health end points (Table 3). The partial correlation
coefficient can be squared to provide an estimate of the vari-
ance of change in QOL-AD scores accounted for by the
change in other clinical outcome measures controlling for
all other baseline variables. These calculations suggest that
the proportion of variance in change of QOL-AD score ac-
counted for by change in other clinical outcome measures
ranged between 0.49% and 12.96%.
Linear regression analysis showed that changes in the clin-
ical/health end points considered showed statistical signifi-
cance in predicting change in QOL-AD scores
(patient-assessed, caregiver-assessed, and weighted), when
controlling for baseline QOL-AD score and baseline demo-
graphic and clinical characteristics (Table 3). All P-values
associated with coefficient estimates are ,.05. The standard
errors of the coefficient estimates are small when compared
with their coefficients. The coefficients for predicting change
Table 1
Baseline demographics for patients with mild Alzheimer’s disease dementia and their caregivers
Demographic Placebo (n 5 663*) Solanezumab (n 5 659*) Total (N 5 1322*)
Patients
Age, years 73.3 (7.9) 73.9 (8.1) 73.6 (8.0)
Female, n (%) 362 (54.6) 346 (52.5) 708 (53.6)
Years since onset of AD symptoms 4.2 (2.6) 4.3 (2.4) 4.3 (2.5)
Years since AD diagnosis 1.9 (1.9) 1.9 (1.8) 1.9 (1.8)
Number of comorbidities 0.5 (0.9) 0.5 (0.9) 0.5 (0.9)
Previous depression, n (%) 206 (31.1) 189 (28.7) 395 (29.9)
Concomitant AD medicine use, n (%) 587 (88.5) 574 (87.1) 1161 (87.8)
Living alone, n (%) 75 (11.3) 71 (10.8) 146 (11.0)
Region, n (%)
USA 261 (39.4) 254 (38.5) 515 (39.0)
EU 168 (25.3) 159 (24.1) 327 (24.7)
Other 234 (35.3) 246 (37.3) 480 (36.3)
Baseline clinical measures; possible score range
MMSE; 0–30 22.5 (2.8) 22.5 (2.8) 22.5 (2.8)
ADAS-Cog 14; 0–90 29.6 (8.8) 30.1 (8.5) 29.9 (8.7)
ADCS-ADL total; 0–78 63.7 (10.8) 63.4 (11.1) 63.6 (11.0)
ADCS-iADL total; 0–56 42.9 (9.5) 42.4 (9.9) 42.6 (9.7)
NPI total; 0–144 9.8 (11.9) 8.4 (11.0)y 9.1 (11.5)
NPI caregiver distress; 1–60 5.6 (6.4) 4.9 (6.2) 5.3 (6.3)
EQ-5D utility (using US utility values); 20.11 to 1 0.84 (0.13) 0.84 (0.14) 0.84 (0.14)
EQ-5D VAS; 0–100 70.8 (22.1) 73.7 (18.6)y 72.2 (20.4)
Caregivers
Age, years 63.6 (13.1) 63.6 (13.0) 63.6 (13.0)
Female, n (%) 413 (62.3) 437 (66.3) 850 (64.3)
Relationship to subject, n (%)
Child 168 (25.3) 178 (27.0) 346 (26.2)
Spouse 417 (62.9) 412 (62.5) 829 (62.7)
Other 75 (11.3) 63 (9.6) 138 (10.4)
Total caregiver timez, median (Q1, Q3), hours 48 (11,120) 60 (12,135) 56 (12,122)
Abbreviations: AD, Alzheimer’s disease; ADAS-Cog, Alzheimer’s Disease Assessment Scale–Cognitive subscale (11-item and 14-item); ADCS-ADL, Alz-
heimer’s Disease Cooperative Study–Activities of Daily Living Inventory; ADCS-iADL, ADCS–instrumental ADL; EQ-5D, EuroQol-5 Dimensions; EU, Eu-
ropean Union; MMSE, Mini–Mental State Examination; NPI, Neuropsychiatric Inventory; Q1, Q3, interquartile range; SD, standard deviation; SOC, standard
of care; VAS, visual analog scale.
NOTE. Data are presented as mean (SD) unless otherwise indicated.
*Number of randomized subjects. The number of subjects included in each analysis varied based on the number of subjects with a baseline value for that
measure.
yP, .05 for comparisons between solanezumab and placebo using a two-sample t test for continuous measures and chi-squared test for categorical measures,
and Wilcoxon rank sum test for median.
zTotal caregiver time in the month before the baseline visit.
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dicting change in QOL-AD patient-assessed scores. Except
for the change in EQ-5D utility scores, all coefficients are
less than one indicating that for every additional one-unit
change in the other clinical outcomes, the change in QOL-
AD score would be expected to increase/decrease by less
than one unit.3.3. Change in QOL according to treatment
Results of the MMRM showed a significant least squares
mean difference favoring solanezumab versus placebo on
patient-assessed QOL-AD scores at 80 weeks (Fig. 1A;
P, .05). The differences between solanezumab and placebo
for caregiver-assessed and weighted QOL-AD at 80 weeks
were not statistically significant (Fig. 1B and C).
Mean change of QOL-AD from baseline to 80 weeks,
correlation coefficient of QOL-AD between baseline and80 weeks, effect size of treatment effect on QOL-AD, and
required sample size estimations for each group are pre-
sented in Table 2. To have 80% power to demonstrate statis-
tical difference (a, .05), a sample size of 1092 patients for
each group is required to detect a 0.12 effect size relative to
placebo on the patient-assessed QOL-AD, 4362 patients for
each group on the caregiver-assessed QOL-AD, and 3205
patients for each group for the weighted QOL-AD.4. Discussion
Results of this study show that patients and caregivers do
not report the same level of QOL for patients with mild AD
dementia. Patients generally rated their QOL-AD scores to
be better than did caregivers. Also, caregivers reported greater
decline over time in patients’ QOL-AD scores. These results
are in agreement with those of other studies conducted using
this disease-specific QOL measure in patients with dementia,
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than do patients themselves [8,12,23–27]. This pattern
appears to hold over the type of setting, with caregivers
rating QOL-AD lower than patients in inpatient settings
[28] as well as in outpatient interventional studies [23]. Inter-
estingly, this disparity between patient and proxy-reported
QOL also seems to occur in other diseases such as end-
stage cancer [29], Parkinson disease [30–32], and after
stroke [33]. Therefore, it is likely that not all of the discrep-
ancy in patient vs. caregiver QOL ratings is due to features
of AD. This suggests there are inherent limitations in using
proxy reports generally to elicit subjective information.
In addition to cross-sectional differences between pa-
tients and caregivers, changes in caregiver-assessed QOL
are greater than those of patient-assessed QOL over time
[25–27]. Indeed, patient-assessed QOL typically shows
only small changes [26]. When reported, patients enrolled
in these studies generally had stages of dementia (mean
baseline MMSE scores of 19.5–24.0) [23–26] similar to
those of the patients in our study and, most commonly, had
baseline mean patient-assessed QOL-AD scores of
25.6–51.7 and caregiver-assessed scores of 24.5–37.9
[8,12,23–26]. Evaluation of patients with mild or very
mild AD (Clinical Dementia Rating Scale score of 0.5 or
1) indicates that patient- and caregiver-assessed QOL-AD
scores begin to diverge early in the course of dementia,
when patients have very mild memory impairment (as deter-
mined by a Clinical Dementia Rating Scale–Sum of Boxes
score of 4 or MMSE score of 25–30) [8], earlier stages
than those of the patients in the present study, and that
patient-assessed QOL measures are less sensitive to disease
progression than those assessed by caregivers [8,23].
Although starting early in the disease course [8], the diver-
gence between patients’ and caregivers’ assessments of pa-
tient QOL is seen across the range of AD dementia
severity (MMSE score range of 0–29; mean score 14.7) [34].
The low-to-moderate correlations between caregiver- and
patient-assessed QOL-AD scores seen in this and other
studies of patients with AD or other forms of dementia
[8,12,23–27,34] as well as the low correlations with other
clinical outcomes may reflect a number of factors. Patient
QOL has been shown to be impacted by disease-related
impaired insight, the number/severity of depressive symp-
toms, irritability, apathy, ADLs, provision of care at home,
and cognitive function [24–26,34]. Clinicians should
consider that an AD patient with anosognosia may be
reporting QOL accurately to their experience. Caregiver-
related factors include differences in the variables affecting
the rating of QOLwhen responding for oneself versus another
(e.g., a patient’s QOL as assessed by the caregiver may reflect
not just the caregiver’s assessment of the patient’s level of
cognition and functioning but also the caregiver’s projection
of what he would feel like if he were the patient but with un-
impaired insight). Caregivers may also be influenced by their
emotions for the patient (e.g., resentment, grief for the loss of
the patient’s identity or the extent of burden they are
Table 3
Partial correlation and linear regression analysis between change in QOL-AD and change in other clinical/health measures after controlling for baseline QOL-
AD, baseline clinical/health measures, and patient baseline clinical and demographic characteristics in the pooled population with mild Alzheimer’s disease
dementia (N 5 1322)
Clinical/health measure
Change in QOL-AD patient-
assessed score Change in QOL-AD caregiver score Change in QOL-AD weighted score
Partial correlation
coefficient*
Coefficient
estimate (SE)y
Partial correlation
coefficient*
Coefficient
estimate (SE)y
Partial correlation
coefficient*
Coefficient
estimate (SE)y
Change in MMSE score 0.11 0.13 (0.03) 0.23 0.28 (0.03) 0.19 0.18 (0.02)
Change in ADAS-Cog 14 score 20.08 20.04 (0.01) 20.24 20.12 (0.01) 20.17 20.07 (0.01)
Change in ADCS-ADL total score 0.12 0.07 (0.01) 0.36 0.15 (0.01) 0.26 0.10 (0.01)
Change in ADCS-iADL score 0.12 0.08 (0.01) 0.35 0.17 (0.01) 0.25 0.11 (0.01)
Change in NPI total score 20.1 20.05 (0.01) 20.32 20.17 (0.01) 20.23 20.09 (0.01)
Change in NPI stress score 20.07 20.07 (0.02) 20.3 20.31 (0.02) 20.19 20.15 (0.02)
Change in EQ-5D utility (US values) 0.16 4.76 (0.87) 0.29 10.54 (0.91) 0.27 6.54 (0.69)
Change in EQ-5D VAS 0.19 0.05 (0.01) 0.24 0.07 (0.01) 0.26 0.05 (0.01)
Abbreviations: AD, Alzheimer’s disease; ADAS-Cog, Alzheimer’s Disease Assessment Scale–Cognitive subscale (14-item); ADCS-ADL, Alzheimer’s Dis-
ease Cooperative Study–Activities of Daily Living Inventory; ADCS-iADL, ADCS–instrumental ADL; EQ-5D, EuroQol-5 Dimensions; MMSE, Mini–Mental
State Examination; NPI, Neuropsychiatric Inventory; QOL-AD, Quality of life in Alzheimer’s disease scale; SE, standard error; SOC, standard of care; VAS,
visual analog scale.
NOTE. All P-values associated with the coefficient estimates are ,.05.
*The partial correlation (Spearman partial rank-order correlation) coefficient reported is the relationship between change in QOL-AD score and change in
other outcomes measures (such as MMSE, ADAS-Cog 14, ADCS-ADL total score, ADCS-iADL, NPI total score, NPI stress score, EQ-5D utility, and EQ-5D
VAS), while controlling the effect of other variables including baseline QOL-AD score, baseline of outcome variable examined, baseline patient demographic,
and clinical characteristics such as age, sex, number of comorbidities, depression (yes/no), and concomitant AD medication (acetylcholinesterase inhibitor or
memantine) use (yes/no); caregiver age, sex, and type of caregiver; region; treatment (solanezumab/placebo); whether the patient lived alone (yes/no); duration
since AD diagnosis; and duration since AD onset.
yEach model evaluated the change in QOL-AD predicted by the change in another clinical/health outcome measure controlled for baseline QOL-AD score,
baseline of outcome variable examined, baseline characteristics: age, sex, number of comorbidities, previous depression (yes/no), concomitant AD medication
(acetylcholinesterase inhibitor or memantine) use (yes/no), caregiver age, and sex, type of caregiver, region, treatment (solanezumab/placebo), whether patient
lives alone, time since AD diagnosis, and time since AD onset.
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presence of depression in caregivers has been shown to have a
significant effect on the way in which they rate patients’ QOL
[13]. In one study of patients with AD and their caregivers,
patients’ QOL evaluations showed a negative relationship
with patients’ depressive mood and a positive relationship
with patients’ ADL, whereas caregivers’ QOL ratings showed
a negative relationship with both patients’ depressive mood
and behavioral disturbances [12]. In another study, the stron-
gest predictor of patient-assessed QOL-AD scores was their
depressive symptoms, whereas functional decline and the
presence of neuropsychiatric symptoms in patients predicted
poor caregiver ratings of patients’ QOL [13]. A recent anal-
ysis found caregivers rated patients’ QOL better than did
the patients themselves when the patient was older, and lower
than the patients’ assessments when NPI total score and care-
giver burden were higher [23]. Further analyses using the cur-
rent data set may provide additional insights into which
patient and caregiver characteristics influence QOL.
The differences between self- and caregiver-reported QOL
are part of the challenge in defining aminimally important dif-
ference (MID). In the placebo group, the average decline from
self-report was less than one point and from caregiver-report
was approximately 1.5 points over 80 weeks, whereas in the
solanezumab group, the average decline from self-report was
about one half of a point and was approximately 1.7 points
as reported by caregivers over 80 weeks. With a lack ofconsistency in self- and caregiver report, this suggests that
different MIDs may be needed depending on who is doing
the reporting. However, no set MID is agreed upon in the liter-
ature. Prior research suggests a change of three points as a
“clinically important difference” or “significant change”
[35,36]. The three-point change previously described used an
anchor-based approach of moving from poor to excellent
health for at least one item on the scale. It is problematic to
apply this three-point change when considering a treatment
that slows disease progression, as the three points exceed the
natural decline ofQOLbyboth self-report and caregiver report
as evident in our placebo group. Importantly, this three-point
MIDwas determined as part of interventionsmeant to improve
QOL, whereas the current therapy is intended to slow disease
progression. Future research should explore whether a
distribution-based approach based on the natural history of
QOL decline might therefore be more relevant and how it
might be applied to both self- and caregiver-reported scores.
Results of our study also show that the QOL-AD was
significantly associated with all the clinical/health outcomes
we considered, although these relationships were generally
modest and strongest when considering caregiver-assessed
QOL (Table 3). Perhaps this is not unexpected, given the
same caregiver was also providing the proxy report on a num-
ber of other clinical measures. These findings are in agree-
ment with the results of other studies of patients with
dementia, which found that caregiver-assessed QOL was
Fig. 1. MMRM analysis* of change from baseline to post-baseline visits in
(A) patient-assessed, (B) caregiver-assessed, and (C) weighted (QOL-AD)
scores for patients with mild Alzheimer’s disease. *The MMRMmodel eval-
uated longitudinal treatment effects of solanezumab or placebo on the change
from baseline in QOL-AD. The model includedQOL scores at baseline, treat-
ment (solanezumab/placebo), visit (as a repeatedmeasure), treatment-by-visit
interaction, and the baseline covariates age, sex, number of comorbidities, pre-
vious depression (yes/no), concomitant AD medication (acetylcholinesterase
inhibitor or memantine) use (yes/no), caregiver age, sex and type, region,
whether patient lived alone, time since AD diagnosis, and time since AD
onset. yP,.05 for statistically significant difference in the solanezumab group
versus the placebo group in patient-assessed QOL-AD at 80 weeks. Abbrevi-
ations: AD, Alzheimer’s disease; MMRM, mixed model repeated measures;
QOL-AD, quality of life in Alzheimer’s disease scale.
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QOL [24–26,34,37]. In a clinical trial population similar to
the one described in this study, a similar modest association
between change in patient-reported QOL-AD was reported
[25], suggesting thatmany different types of factors influence
change in QOL over time in clinical trial populations.Prespecified secondary analyses of the phase-III trials
(EXPEDITION and EXPEDITION 2) included in the cur-
rent analyses have suggested a significant benefit of solane-
zumab on cognition and function in patients with mild AD
dementia [18]. Although a significant difference in patient-
assessed QOLwas detected favoring solanezumab, no statis-
tically significant between-treatment difference was noted in
caregiver-assessed QOL. Given the perception that patient-
assessed QOL may be less reliable than caregiver-assessed
QOL, this inconsistency in treatment effect was somewhat
surprising. Several factors should be considered when inter-
preting these results. It is possible that these results support
the suggestion that patients with mild AD dementia do retain
enough insight to evaluate their current QOL and discern any
impact of treatments (replication in future clinical trials
would lend additional support). Because deterioration in
cognition has been shown to precede functional decline in
patients with mild AD dementia [38], and an obvious func-
tional decline in patients may be necessary before caregivers
perceive a change in QOL, caregiver-assessed QOL may be
less sensitive to treatment effects over the short term. Some-
what paradoxically, caregiver-assessed QOL-AD was more
strongly associated than patient-assessed QOL-AD with
other clinical measures, including the key efficacy measures
of cognition and iADL that demonstrated a treatment effect
in prior analyses [18]. These findings highlight the
complexity of AD, particularly when faced with the chal-
lenges of obtaining patients’ self-assessment of the impact
of the disease on their daily lives.
This study has several potential limitations. As discussed,
it is possible this study duration was too short to detect a
treatment effect on caregiver-assessed QOL in these patients
with mild AD dementia. Additionally, although the QOL-
AD is validated across a wide range of cognitive levels
(MMSE. 10), if the decline in this scale is less than 2 points
during a clinical trial, a treatment effect, such as from sola-
nezumab, may not be reliably detected. Even if changes in
QOL-AD are associated with changes in clinical outcomes
in practice, other factors may also be involved so the rela-
tionship may not be a direct one-to-one ratio, or the associ-
ation may be nonlinear. Another possibility is that QOL may
not be associated with cognitive or functional response, as
suggested by the results of a small study in 47 patients
with probable mild or moderate AD [27]. Finally, as AD pro-
gresses and cognition is lost, function becomes impaired. Pa-
tient awareness of their cognitive loss also becomes
impaired and may interfere with their self-assessment of
QOL, so the window for assessing a treatment effect using
QOL measures may be limited. As stated previously, neuro-
psychiatric symptoms, such as depression, that occur early in
AD when cognition is less impaired and insight is main-
tained, may have a profound effect on QOL ratings in mild
dementia, whereas QOL may be less affected by these vari-
ables during later stages of dementia.
Assessing changes in patients’ QOL, due to either disease
progression or treatment modification, can be challenging
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[8,12,13], the fact that QOL may not decline significantly
during a clinical study of typical duration (18–24 months in
patients with mild AD dementia) and, as mentioned earlier,
the disease itself may compromise patient insight. Future
studies to confirm the value of the QOL-AD as a measure of
patient QOL in relatively short-term trials of 18–24 months
would therefore be of benefit. Consideration of other QOL
scales used or new ways to measure QOL in AD would also
be useful to help identify the optimalmeasure for future inves-
tigations. Previous studies have shown a moderate and signif-
icant correlation between caregiver-assessed QOL-AD and
the caregiver-assessed Health Utility Index Mark 3 (HUI-3)
[25] and patient- and caregiver-assessed QOL-AD scores
and the more generic EQ-5D scale (as rated by both patients
and caregivers) [24]. Although the QOL-AD and EQ-5D per-
formed similarly [24], HUI-3 scores were more strongly
associated with clinical end points measuring cognition, func-
tion, behavior, and dependence than were patient- or
caregiver-assessed QOL-AD scores [25].
QOL remains an important consideration when
describing the patient experience in AD as well as when
considering broader benefits of new therapies and multi-
modal interventions. However, the current data suggest
that very large sample sizes would be needed to detect a
treatment effect based on QOL, as compared to a primary
outcome like cognition that is central to the disease process,
particularly when considering proxy-reported QOL-AD.
The practical implications of conducting studies with such
high patient numbers are likely to manifest as much longer
cycle times for clinical trials as enrollment periods are
lengthened. The results of ongoing trials (assuming positive
outcomes on primary end points) will, therefore, be of crit-
ical importance in determining if a treatment effect on
QOL can reasonably be expected within the logistic realities
of the current trial design paradigm.
This work is informative for future trials of disease-
modifying therapies in AD. Although the present results
showed a relatively slow rate of decline in QOL scores in pa-
tients with AD, a statistically significant treatment effect
with solanezumab was noted. Replication of the observed
patient-assessed treatment effects on QOLwill provide addi-
tional insights into the ability of QOL to be used as a reliable
index of clinical meaningfulness. Future studies may also
inform whether 80 weeks are sufficient time to detect a treat-
ment effect on patient- or caregiver-assessed QOL.5. Conclusion
Our study results show that patient- and caregiver-assessed
QOL measures reflected different perceptions of QOL, with
caregivers rating patient QOL worse than did patients them-
selves. Although change in caregiver-assessed patient QOL
was more highly correlated with the clinical/health measures
evaluated than patient-assessed QOL, patient-assessed QOL
did show a significant treatment effect in favor of solanezu-mab. Confirmation of the present findings in future trials
and other interventional studies that demonstrate a positive
treatment effect on cognition and other clinical outcomes
will help those with an interest in AD to better understand
how QOL generally, and the QOL-AD in particular, are
impacted by interventions that slow disease progression.
These insightswill be an important part of helping researchers
and clinicians understand how to explain the clinical mean-
ingfulness and impact of interventions in AD.Acknowledgments
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1. Systematic review: Literature searches indicate that,
until recently, few studies have evaluated quality of
life (QOL) in patients with Alzheimer’s disease
(AD) or effects of treatment on patients’ QOL. To
explore whether QOL reflects clinical meaningful-
ness in patients with AD, pooled data from patients
with mild AD dementia from two phase-III trials of
solanezumab were evaluated.
2. Interpretation: Our study confirms that caregivers
rate patients’ QOLworse than do patients themselves
and that patients’ QOL is modestly correlated with
clinical/health measures. Although caregiver-rated
QOL showed a faster rate of decline, a treatment
effect on QOL-AD from solanezumab was noted in
patient-report only. These results, along with the
relatively slow decline in QOL scores of patients
with mild AD dementia, suggest that QOLmay be an
important but complex index of clinical meaning-
fulness in clinical trials that requires further exami-
nation.
3. Future directions: Further studies are needed to
confirm whether longer trials will allow demonstra-
tion of a treatment effect on QOL and elucidate
which subdomains of QOL-AD measures may be
most relevant to patients with mild AD dementia.
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